C07K 2319/912
Containing a gpi anchor
Official title: containing a GPI (phosphatidyl-inositol glycane) anchor
C07K2319/912 (Containing a gpi anchor) appears on 21 US grants and 35 published applications in this corpus.
Search patents in C07K- Granted patents
- 21
- Published applications
- 35
- Assignees
- 32
- Inventors
- 96
- Latest grant
- 2 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 1 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 2 | 1 |
| 2019 | 1 | 0 |
| 2020 | 0 | 3 |
| 2021 | 0 | 7 |
| 2022 | 0 | 4 |
| 2023 | 5 | 1 |
| 2024 | 0 | 5 |
| 2025 | 5 | 7 |
| 2026 | 0 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Engineered VEGF variants for retinal neuroprotection, promotion of axon growth and axon regeneration2 Sep 2025US 12,404,312 B2Massachusetts Eye and Ear Infirmary
- Engineered extracellular vesicles comprising fusion proteins12 Aug 2025US 12,384,828 B2Diadem Biotherapeutics Inc.
- Targeted ligand-payload based drug delivery for cell therapy1 Jul 2025US 12,343,403 B2Purdue Research Foundation
- Cell-associated heterologous food and/or feed enzymes1 Jul 2025US 12,344,847 B2Danstar Ferment AG
- Enhanced immunogenicity for GPI-anchored antigens11 Mar 2025US 12,247,086 B2NantBio, Inc.
- Engineered furin cleavage sequences for co-expression of multiple genes in mammalian cells20 Aug 2026US 2026/0242821 A1Agency for Science, Technology and Research
- Recombinant immune cell-based cell therapeutic agent for treating cancer via polyclonal expansion of tumor-infiltrating t cell in tumor6 Aug 2026US 2026/0224615 A1Korea Advanced Institute of Science and Technology
- Recombinant opcml fusion protein optimizing opcml d1 domain homodimerisation and methods of use for cancer treatment28 May 2026US 2026/0146069 A1
- Cell-associated heterologous food and/or feed enzymes28 Aug 2025US 2025/0270569 A1
- Targeted Ligand-Payload Based Drug Delivery for Cell Therapy21 Aug 2025US 2025/0262313 A1Purdue Research Foundation
Most cited
By later US patents
- Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor164US 5,374,548 AGenentech, Inc. · 1994
- Recombinant DNA molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence33US 5,223,394 ABiogen, Inc. · 1993
- Membrane anchor fusion polypeptides23US 5,109,113 AGenentech, Inc. · 1992
- Decay accelerating factor (DAF) and nucleic acids encoding it14US 5,763,224 AGenentech, Inc. · 1998
- Glycosyl-phosphatidylinositol-specific phospholipase D13US 5,418,147 AHoffmann-La Roche Inc. · 1995